Member Info for GlenFidrich

Someone must have posted this at the time, but I missed it. It's a good overview of where Sareum is at, for any new investors contemplating taking the plunge, or for any existing investors who might be experiencing the extreme frustration that often plagues us as we await news and who might just be thinking of jumping ship.
https://www.thearmchairtrader.com/sareum-holdings-share-price-forecast-december/
Lots to look forward to in the near future.

I'm invested here, and also in SAR. I see a lot of similarities between the 2 companies, yet HEMO has a mcap of 16m and SAR has a mcap of 167m. Either HEMO is undervalued or SAR is overvalued, I guess, but I can honestly see Hemo at 10p minimum by the end of 2022. I hate making SP predictions, by the way, so DYOR obviously. But just think HEMO is so undervalued at the moment. GLA for 2022.

3rd item on the 'GFM Live RNS' option, if you press the icon?
https://www.lse.co.uk/rns/GFM/winter-olympics-games-extension-6tgu17xdoac4k0d.html
Always useful to read through historic RNSs before making any kind of investment decision, amongst other things, of course.

Colbaltblue, I think you'll find the board has already given us "a compelling reason [actually, more than one] for the planned action" at the last AGM meeting: "The Board is of the opinion that the high number of shares outstanding (over 3.3 billion) and the low absolute share price negatively affects investors' perception of the Company and considers a share consolidation to be in the best interests of the Company and its shareholders. A consolidation would reduce the number of shares outstanding and increase the relative price, which could be more attractive to a broader range of institutional investors and other members of the investing public." Not sure what more you want them to say?

Same to you, Warty, and wish your wife a speedy recovery. Here's hoping 2022 brings you, your family, and all much happiness.
Apologies again for my clumsy attempt at humor, at what must have been a very worrying time. No excuses...

Warty, profuse apologies if I overstepped the mark yesterday. Was just trying to inject a bit of humor into what I know is a frustrating period. Being stiffed by SRRA, and now also by PH, has left a sour taste, I must admit. I just think we will get our just reward in the end, so long as we hang in there. Hope that I'm still alive to enjoy the spoils mind you.

1) Yesterday, Hemo was valued at 18.6m pounds. Today, we're now worth 16.6m. (SP x shares in issue/market cap.)
2) Sells today = roughly 12m shares, vs buys today = 5m. Therefore sells = 7m net (roughly, let's say, 130,000 pounds worth)
3) So, we lose 2m GBP from market cap based on net sales of 130,000 GBP? Can anyone explain? How can this possibly be fair?
4) Beware setting stop losses - the MMs can see these, and drop the bid to trigger them. Common practice.
5) On another share, we all joined forces to prevent MMs from "borrowing" our shares (without our knowledge) by setting minimum sell prices (vastly inflated), thereby limiting such practice. Most share platforms allow this, but you'll need to update it regularly (I think once a week, or so).
I should add that points 4 & 5 were occurring on an AIM share. Not sure if such practice is permitted with a share like HEMO listed on the main LSE, but it certainly appears to be subject to the usual shenanigans one finds on the AIM.

...a little less than 12m shares traded and some are fretting over a 9% drop? If we were seeing volume in the 100m range I might take note, but this is the MMs doing what they do best. Making their daily 10-15% margins, disrupting the market for their end of year knees up. It's clear as day, but for PIs a dangerous game to play. Best just to sit on your hands and remember why you invested here in the first place. News will drop when you're least expecting it and you will not want to be scrambling to buy when it does. GLA.

Warty, full of Christmas cheer, I see. The gin bottles, wine bottles, and the port bottle must all be fully empty!
Everyone knows the game here, so unless you're desperate for the money (to replenish said bottles), everyone needs to chill out. It'll probably finish the day blue if I know their little game. Patience required.

Apologies if someone has already posted this, but I thought it might be useful to see what a consolidation might look like (in terms of shares in issue) at various ratios. So, here goes:
10:1 = 340,300,000 = 52p per share
20:1 = 170,150,000 = 104p per share
30:1 = 113,433,333 = 156p per share
40:1 = 85,075,000 = 208p per share
50:1 = 68,060,000 = 260p per share
The question is, at what consolidation ratio does Sareum suddenly become attractive to institutional investors, based on SP/shares (or paucity thereof) in issue? My preference would be for a 50:1 consolidation, based on the fact that I find companies with a limited number of shares in issue (<100m) more attractive. This probably sounds irrational to some, but it's just my own thoughts. Anyone care to add an opinion?

https://www.msn.com/en-gb/health/medical/decisive-use-of-astrazeneca-vaccine-may-have-spared-uk-from-omicron-crisis-hitting-europe/ar-AAS9Rjg?li=BBoPWjQ
The final paragraph caught my eye: '“I do think we've lost the battle with transmission. There's no vaccine that is going to change that. I think we should focus on the cellular immune response, and it may just get us out of the woods.”' Isn't this precisely what HEMO's CBR project is working on i.e. "to programme immune cells to destroy viral pathogens (such as SARS-CoV-2)"? Exciting times indeed for HEMO. GLA.

For anyone in any doubt as to what a positive year Sareum has had, look no further than the one year chart, which plots the SP performance in said period:
https://www.google.com/finance/quote/SAR:LON?window=1Y
An almost 125% rise for those of us who just sat on our hands and waited. Not bad, I would suggest, yet for some the grass is always greener. Good luck all, and hope 2022 gives us all a similar return (at least)!

I just thought I might examine the RNS point by point, as they occur to me:
1) "The Placing and Subscription will enable the Group to move forward without the need to re-evaluate its strategy and outlook." Well, after the events of today, and last Friday (the 5pm RNS you'll remember), I actually think a complete strategic review is critical, with or without the further funding.
2) 2.55m pounds, at current burn rate (apparently 1.4m in 6 months - see the last RNS), will stave off the inevitable for about a year. Then what?
3) "The Group's interim results published on 22 September 2021 highlighted the increase in commercial traction with active users up 47 per cent and customers up to approximately 37." Approximately 37? What, you're having trouble counting up to 37 there, Mark? I just don't understand how the number of customers one has can be approximate. It's like a teacher telling a parent that there are approximately 30 kids in the class! It's so vague and amateurish.
4) Then we get the three paragraphs in bold text. They essentially repeat what was explained in the RNS from last Friday. So it's kind of patronizing to repeat it, in bold, as if we're all too stupid to get it. We get that you've burned through a whopping 1.4m quid in 6 months. We get that you're intending to use the proceeds to invest in the business (and, by the way, ensure you all continue to take home your inflated salaries). We also get (somewhat alarmingly for me) that this fundraise is expected to get DMTR out of shtum only for the next 12 months. I repeat. THEN WHAT???
There's more, but I've had enough. Sold out, I'm sorry to say.

Oh no, they're not. Wait! Oh yes, they are.

Just when you thought it was safe to come out. Not even our resident prophet of doom (#odiouslittleman) predicted this. Utter shambles. MW needs to go, and fast.

...for me, at least, of the early days in SAR. Lots of expectation, followed by confidence-sapping periods of disappointment. Hugely promising IP, yet greatly undervalued by the market. Whatever your entry price, my experience in SAR has been to buy, hold, and (if you can) top up on the dips. But, essentially, hold, since that is when you will likely multibag. Sure, you can trade it for your 10% profit here and there, but you will be in danger of missing out on the '50% rise in a day' kind of increases. And, if you compare the shares in issue (3.2 billion vs roughly 1 billion) you might also gain an insight as to how far and how fast the SP here might increase. Finally, HEMO is arguably further down the road to clinical trials than SAR yet our market cap is a mere 19m squids, whereas SAR's is 175m. Go figure. I'm invested in both, for the sake of transparency, but I'm feeling HEMO has the upper hand in the 'potential stakes' at the moment. GLA, whatever you decide.

Not invested here, but interested. Just wondering. How many other companies are manufacturing what AVON manufactures? It seems to me a pretty niche market, with AVON enjoying a competitive advantage. Thus a classic Warren Buffet-type of investment. Based on the historical price charts, this is looking cheap, surely?

Copy that, and just to say a huge thx to all the posters who make this BB by far the best! Happy New Year - 2022 will be our year, of that I'm sure (well, kind of, hopefully!).

So I'm fairly new here, although HEMO has been on my watchlist for quite some time. I just wanted to echo some posters' comments about how pleasant this BB is, and thank those who share information freely. I know first hand the devastation that AML and ALL can wreak on the human body. If HEMO can assist in prolonging the lives of those afflicted, and provide hope for the families left reeling from the diagnoses of loved ones, then I'm all in. Merry Christmas everyone, and here's hoping 2022 is transformative for everyone invested here, whatever the outcome you wish for.

Thx for the heads up, Trek.